Zidovudine-treated HIV
Anemia due to zidovudine in HIV-infected patients

PROCRIT® is indicated for the treatment of anemia due to zidovudine administered at ≤4,200 mg/week in HIV-infected patients with endogenous serum erythropoietin levels of ≤500 mU/mL.

Established dosing and titration for HIV patients with anemia due to zidovudine1


*Initiation dose: 7,000 U TIW for a 70-kg patient.
The PROCRIT® full Prescribing Information recommends that patients be titrated to achieve and maintain the lowest Hb level sufficient to avoid the need for blood transfusion and not to exceed the upper safety limit of 12 g/dL.

  • For adult patients with serum erythropoietin levels ≤500 mU/mL who are receiving a dose of zidovudine ≤4,200 mg/week, the recommended starting dose for PROCRIT® is 100 U/kg, IV or SC, TIW
  • If Hb does not increase after 8 weeks of therapy, increase PROCRIT® dose by approximately 50 U/kg to 100 U/kg at 4- to 8-week intervals until Hb reaches a level needed to avoid RBC transfusions or 300 U/kg
  • Withhold PROCRIT® if Hb exceeds 12 g/dL. Resume therapy at a dose 25% below the previous dose when Hb declines to <11 g/dL
  • Discontinue PROCRIT® if an increase in Hb is not achieved at a dose of 300 U/kg for 8 weeks
divider

References
  1. PROCRIT® Prescribing Information. Janssen Products, LP.
 
Indications and Important Safety Information
EXPAND    Expand ISI
Indications
Expand ISI
Important Safety Information
Expand ISI